KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EBT (2016 - 2025)

Biogen (BIIB) has 17 years of EBT data on record, last reported at -$56.0 million in Q4 2025.

  • For Q4 2025, EBT fell 119.21% year-over-year to -$56.0 million; the TTM value through Dec 2025 reached $1.6 billion, down 18.34%, while the annual FY2025 figure was $1.6 billion, 18.34% down from the prior year.
  • EBT reached -$56.0 million in Q4 2025 per BIIB's latest filing, down from $557.3 million in the prior quarter.
  • Across five years, EBT topped out at $1.4 billion in Q3 2022 and bottomed at -$141.2 million in Q3 2023.
  • Average EBT over 5 years is $504.8 million, with a median of $457.9 million recorded in 2024.
  • Peak YoY movement for EBT: skyrocketed 419.41% in 2024, then crashed 119.21% in 2025.
  • A 5-year view of EBT shows it stood at $405.0 million in 2021, then skyrocketed by 49.09% to $603.8 million in 2022, then plummeted by 51.71% to $291.6 million in 2023, then dropped by 0.03% to $291.5 million in 2024, then plummeted by 119.21% to -$56.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$56.0 million in Q4 2025, $557.3 million in Q3 2025, and $744.0 million in Q2 2025.